Yamashita et al. performed immunohistochemistry on lung adenocarcinoma tissue samples to investigate the predictive value of HE4 for patient outcome and found that the five-year disease-free survival in the HE4-positive group (44.6%) was significantly lower than that in the HE4-negative group (82.3%, p = 0.001). Here, WFDC2 is linked to lung adenocarcinoma.